[Endocannabinoids: therapeutic perspectives in chronic liver diseases]

Gastroenterol Clin Biol. 2007 Mar;31(3):255-8. doi: 10.1016/s0399-8320(07)89369-9.
[Article in French]
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Appetite Depressants / therapeutic use
  • Cannabinoid Receptor Modulators / physiology*
  • Cannabinoids / antagonists & inhibitors*
  • Chronic Disease
  • Disease Models, Animal
  • Disease Progression
  • Endocannabinoids*
  • Fatty Liver / prevention & control
  • Glycolysis / drug effects
  • Hepatitis C, Chronic / complications
  • Hepatocytes / drug effects
  • Humans
  • Hypertension, Portal / drug therapy
  • Lipogenesis / drug effects
  • Liver / drug effects
  • Liver / metabolism
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / prevention & control
  • Liver Diseases / drug therapy*
  • Obesity / drug therapy
  • Piperidines / therapeutic use
  • Pyrazoles / therapeutic use
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB1 / physiology
  • Receptor, Cannabinoid, CB2 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB2 / physiology
  • Rimonabant

Substances

  • Appetite Depressants
  • Cannabinoid Receptor Modulators
  • Cannabinoids
  • Endocannabinoids
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • Rimonabant